STOCK TITAN
  1. Home
  2. Sec-filings
  3. TWST
  4. [Form 4] Twist Bioscience Corp Insider Trading Activity

Twist Bioscience (NASDAQ: TWST) COO stock sale in 10b5-1 plan filing

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Twist Bioscience Corp President and COO Patrick John Finn reported an option exercise and share sale in the company’s stock. On January 13, 2026, he exercised a stock option for 3,279 shares of common stock at an exercise price of $8.82 per share and acquired those shares directly.

On the same date, he sold 23,279 shares of Twist Bioscience common stock at a price of $40 per share in an open-market transaction. After these transactions, Finn directly owned 312,883 shares of common stock. The filing notes that these transactions were carried out under a previously adopted Rule 10b5-1 trading plan put in place on May 13, 2025.

Positive

  • None.

Negative

  • None.
Insider Finn Patrick John
Role President and COO
Sold 23,279 shs ($931K)
Type Security Shares Price Value
Exercise Stock Option (right to buy) 3,279 $0.00 --
Exercise Common Stock 3,279 $8.82 $29K
Sale Common Stock 23,279 $40.00 $931K
Holdings After Transaction: Stock Option (right to buy) — 0 shares (Direct); Common Stock — 336,162 shares (Direct)
Footnotes (1)
  1. The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 13, 2025. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vested on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Finn Patrick John
(Last) (First) (Middle)
C/O TWIST BIOSCIENCE CORPORATION
681 GATEWAY BLVD.
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President and COO
3. Date of Earliest Transaction (Month/Day/Year)
01/13/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/13/2026 M 3,279(1) A $8.82 336,162 D
Common Stock 01/13/2026 S 23,279(1) D $40 312,883 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $8.82 01/13/2026 M(1) 3,279 (2) 09/28/2027 Common Stock 3,279 $0 0 D
Explanation of Responses:
1. The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 13, 2025.
2. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vested on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
Remarks:
/s/ Kendra Fox, as Attorney-in-Fact for Patrick John Finn 01/15/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

Who is the insider in this Twist Bioscience (TWST) Form 4 filing?

The insider is Patrick John Finn, who serves as President and Chief Operating Officer of Twist Bioscience Corp.

What stock option transaction did Patrick John Finn report for Twist Bioscience (TWST)?

On January 13, 2026, Finn exercised a stock option (right to buy) for 3,279 shares of Twist Bioscience common stock at an exercise price of $8.82 per share.

How many Twist Bioscience (TWST) shares did Patrick John Finn sell and at what price?

Finn reported selling 23,279 shares of Twist Bioscience common stock on January 13, 2026 at a price of $40 per share.

How many Twist Bioscience (TWST) shares does Patrick John Finn own after the reported transactions?

Following the reported transactions, Patrick John Finn directly owned 312,883 shares of Twist Bioscience common stock.

Were the Twist Bioscience (TWST) insider transactions made under a Rule 10b5-1 trading plan?

Yes. The filing states that the transactions were effected under a Rule 10b5-1 trading plan that Patrick John Finn previously adopted on May 13, 2025.

What are the key vesting terms of the Twist Bioscience (TWST) stock option exercised by Patrick John Finn?

The option is immediately exercisable. 10% of the shares vested on September 28, 2017, 15% vested on September 28, 2018, and 1/48th of the shares vested on each monthly anniversary thereafter, subject to Finn’s continuous service.